Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of DYP688 in Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
2023-509451-14-00Phase 2Suspended
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of DYP688 in intraocular melanoma and melanoma (5 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of dose limiting toxicities (DLTs), Incidence and severity of adverse events and serious adverse events (Phase I) and 2 more. Started Jul 2024; status: suspended.
02
Drugs
DYP688
03
Conditions
intraocular melanomamelanoma
Beyond the preview
Go deeper on 2023-509451-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509451-14-00.